Study of the Disease Process of Lymphangioleiomyomatosis

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Study ID
NCT00001465
Status
Recruiting
Apply to this trial

Conditions

  • Lung Disease
  • Lymphangioleiomyomatosis
  • Pneumothorax
  • Tuberous Sclerosis

Eligibility Criteria

Sex
ALL
Age
16 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Toshibia Aquilion One CT — DEVICE
    The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.

Study Details

Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals. ...

Key Dates

Start date
Dec 18, 1995
Status verified
Apr 2026

Study Design

Enrollment
2,000 participants (estimated)

Arms

  • Arm: LAM
    Patients with tissue diagnosis of LAM may be admitted for evaluation every six months, or as deemed necessary for research

Primary Outcome Measure

Define the clinical course of the disease LAM andelucidate the pathogenesis of LAM at cellular and molecular levels [ Time Frame: on going ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
National Institutes of Health Clinical CenterBethesdaMaryland20892-

Find similar trials in Bethesda, MD

By research site
National Institutes of Health Clinical Center· Bethesda, MD

Related Studies